UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
NCT Number: NCT03411070
This pilot clinical trial will evaluate whether the SCOUT reflector can be used to tag abnormal lymph nodes in patients with breast cancer prior to chemotherapy for targeted removal at the time of surgery. The SCOUT localization system with the SAVI reflector is non-radioactive and completely internal so can be placed into an abnormal lymph node prior to chemotherapy treatment, which theoretically will allow easier identification and therefore more reliable targeting of the abnormal lymph node for surgical removal.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Early Phase 1
Los Angeles, California, 90095, United States
PRIMARY OBJECTIVES:
I. Percentage of patients with successful retrieval of the reflector confirmed by specimen radiography.
II. Percentage of patients with successful retrieval of the biopsied node, confirmed by presence of clip, biopsy changes or treatment-related changes on pathology.
SECONDARY OBJECTIVES:
I. Total number of lymph nodes removed. II. Percentage of patients in which clipped node was a sentinel node. III. Percentage of patients with nodal pathologic complete response (PCR). IV. Residual cancer burden (RCB) score for patients with residual nodal disease.
V. Percentage of patients requiring axillary dissection. VI. Days prior to surgery of reflector insertion.
OUTLINE:
Patients undergo image-guided placement of the SCOUT reflector prior to course 2 of standard of care neoadjuvant chemotherapy. Patients undergo standard of care surgery approximately 4-8 weeks after chemotherapy completion.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Undergo SCOUT reflector placement
Other names: IMPLANTED
Undergo surgery
Time frame: Up to 2 years
Time frame: Up to 2 years
Time frame: Up to 2 years
Time frame: Up to 2 years
Time frame: Up to 2 years
Time frame: Up to 2 years
Time frame: Up to 2 years
Time frame: Up to 2 years
Time frame: Up to 2 years
All adverse events due to these procedures will be recorded and reported to the institutional review board (IRB).
Jonsson Comprehensive Cancer Center
Other
Using Radar Technology to Tag Abnormal Lymph Nodes for Removal During Surgery Following Neoadjuvant Chemotherapy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07483034
Anxiety Disorders, Behavior
Zagreb, City of Zagreb, Croatia
View Trial DetailsNCT04054557
Breast Carcinoma In Situ, Breast Diseases
Washington Township, New Jersey, United States
View Trial DetailsNCT03317405
Adenocarcinoma, Breast Carcinoma In Situ
Los Angeles, California, United States
View Trial DetailsNCT02689427
Breast Diseases, Breast Neoplasms
Houston, Texas, United States
View Trial Details